View:
Download DOC
Download PDF
Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 27, 2012

 

 

TARGACEPT, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-51173   56-2020050

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

200 East First Street, Suite 300

Winston-Salem, North Carolina

   27101
(Address of principal executive offices)   (Zip Code)

(336) 480–2100

Registrant’s telephone number, including area code

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 8.01 Other Events.

Targacept, Inc. and AstraZeneca have determined to discontinue the Phase 2b clinical trial of TC-5214 as a “switch” monotherapy for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant treatment, known as the EXPLORER study. Notification of the study discontinuation to applicable regulatory authorities and institutional review boards is in process. Earlier in March 2012, Targacept and AstraZeneca announced that the two companies would not pursue a regulatory filing for TC-5214 as an adjunct to antidepressant treatment for patients with MDD.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  TARGACEPT, INC.
Date: March 27, 2012  

/s/ Peter A. Zorn

  Peter A. Zorn
  Senior Vice President, Legal Affairs, General Counsel and Secretary